Abstract
Neuronal cell dysfunction and death are cardinal features of Alzheimer disease and a great deal of effort is being expended not only to understand factors involved in the cause and progression of disease (i.e., disease initiators and propagators) but, ultimately, the precise mechanism by which neurons die (for want of a better word, the terminators). Understanding each and every component of the complex pathway that ultimately leads to disease (a clinical phenotype) is clearly of paramount importance for the development of effective therapeutic strategies. Of particular intrigue for many scientists, perhaps the more macabre among us, has been to decipher the final event - namely cell death. Broadly speaking, cell death falls into two categories, apoptotic and necrotic. The former, apoptosis, by definition, is a controlled event; thereby offering the potential for intervention, whereas necrosis is a more stochastic process. Since many of the propagators and exacerbators involved in Alzheimer disease are pro-apoptotic, it is not surprising that certain aspects of apoptosis are evident. However, it would be a mistake to call this apoptosis. In fact, as reviewed herein, the chronic course of disease together with the necessarily slow rate of neuronal death makes apoptotic cell death in Alzheimer disease a mathematical improbability. The numbers simply do not add up.
Keywords: Alzheimer disease, apoptosis, cell death, neurodegeneration
Current Alzheimer Research
Title: Apoptosis in Alzheimer Disease: A Mathematical Improbability
Volume: 3 Issue: 4
Author(s): Xiongwei Zhu, Arun K. Raina, George Perry and Mark A. Smith
Affiliation:
Keywords: Alzheimer disease, apoptosis, cell death, neurodegeneration
Abstract: Neuronal cell dysfunction and death are cardinal features of Alzheimer disease and a great deal of effort is being expended not only to understand factors involved in the cause and progression of disease (i.e., disease initiators and propagators) but, ultimately, the precise mechanism by which neurons die (for want of a better word, the terminators). Understanding each and every component of the complex pathway that ultimately leads to disease (a clinical phenotype) is clearly of paramount importance for the development of effective therapeutic strategies. Of particular intrigue for many scientists, perhaps the more macabre among us, has been to decipher the final event - namely cell death. Broadly speaking, cell death falls into two categories, apoptotic and necrotic. The former, apoptosis, by definition, is a controlled event; thereby offering the potential for intervention, whereas necrosis is a more stochastic process. Since many of the propagators and exacerbators involved in Alzheimer disease are pro-apoptotic, it is not surprising that certain aspects of apoptosis are evident. However, it would be a mistake to call this apoptosis. In fact, as reviewed herein, the chronic course of disease together with the necessarily slow rate of neuronal death makes apoptotic cell death in Alzheimer disease a mathematical improbability. The numbers simply do not add up.
Export Options
About this article
Cite this article as:
Zhu Xiongwei, Raina K. Arun, Perry George and Smith A. Mark, Apoptosis in Alzheimer Disease: A Mathematical Improbability, Current Alzheimer Research 2006; 3 (4) . https://dx.doi.org/10.2174/156720506778249470
DOI https://dx.doi.org/10.2174/156720506778249470 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Brain-gut Axis-where are we now and how can we Modulate these Connections?
Current Neuropharmacology Aluminum Induced Immunoexcitotoxicity in Neurodevelopmental and Neurodegenerative Disorders
Current Inorganic Chemistry (Discontinued) Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Role of Wnt Signaling in the Control of Adult Hippocampal Functioning in Health and Disease: Therapeutic Implications
Current Neuropharmacology The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
Current Drug Targets Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) A Novel Role of the STAT3 Pathway in Brain Inflammation-induced Human Neural Progenitor Cell Differentiation
Current Molecular Medicine Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Neurohypophyseal Dysfunction During Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Anti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets